VCAM1 and brain inflammatory disease: Previous studies have demonstrated that targeted iron-oxide-based MR-contrast agents are able to create hypo-intense signals on T2*-weighted images in regions of VCAM-1 or P-selectin expression in mouse models of atherosclerosis and brain inflammation[17-19].